Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non- myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance

Transplantation

Volumn 68, Issue 9, 1999, Pages 1348-1355

  Wekerle, Thomas ^a,c   Sayegh, Mohamed H ^b   Ito, Hiroshi ^a   Hill, Joshua ^a   Cnandraker, Anil ^b   Pearson, Denise A ^a   Swenson, Kirsten G ^a   Zhao, Guiling ^a   Sykes, Megan ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE ANTIBODY;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CADAVER DONOR; CHIMERA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HELPER CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN GRAFT; WHOLE BODY RADIATION;

EID: 0033571542     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199911150-00022     Document Type: Article

References (51)

1. Nikolic B, Sykes M. Mixed hematopoietic chimerism and transplantation tolerance. Immunol Res 1997; 16: 217.
2. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307(5947): 168.
3. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a non-lethal preparative regimen. J Exp Med 1989; 169: 493.
4. Nomoto K, Yung-Yun K, Omoto K, Umesue M, Murakami Y, Matsuzaki G. Tolerance induction in a fully allogeneic combination using anti-T cell receptor-αβ monoclonal antibody, low dose irradiation, and donor bone marrow transfusion. Transplantation 1995; 59: 395.
5. Colson YL, Li H, Boggs SS, Patrene KD, Johnson PC, Ildstad ST. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 1996; 157: 2820.
6. Tomita Y, Sachs DH, Khan A, Sykes M. Additional mAb injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mAbs and 3 Gy whole body irradiation. Transplantation 1996; 61: 469.
7. Tomita Y, Khan A, Sykes M. Mechanism by which additional monoclonal antibody injections overcome the requirement for thymic irradiation to achieve mixed chimerism in mice receiving bone marrow transplantation after conditioning with anti-T cell mAbs and 3 Gy whole body irradiation. Transplantation 1996; 61: 477.
8. Sayegh MH, Turka LA. The role of T cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338: 1813.
9. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434.
10. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.
11. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187: 2037.
12. Elwood ET, Larsen CP, Cho HR, et al. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 1998; 65: 1422.
13. Konieczny BT, Dai Z, Elwood ET, et al. IFN-γ is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. J Immunol 1998; 160: 2059.
14. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4Ig. Transplantation 1994; 57: 1701.
15. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801.
16. Markees TG, Phillips NE, Noelle RJ, et al. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Transplantation 1997; 64: 329.
17. + T cells, interferon-γ, and CTLA4. J Clin Invest 1998; 101: 2446.
18. Sykes M, Romick ML, Hoyles KA, Sachs DH. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med 1990; 171: 645.
19. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792.
20. Wallace PM, Johnoson JS, MacMaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation 1994; 58: 602.
21. Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 1979; 150: 580.
22. Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a non-myeloablative regimen. J Immunol 1994; 153: 1087.
23. Scollay R, Jacobs S, Jerabek L, Butcher E, Weissman I. T cell maturation: thymocyte and thymus migrant subpopulations defined with monoclonal antibodies to MHC region antigens. J Immunol 1980; 124: 2845.
24. Zhao Y, Swenson K, Sergio JJ, Arn JS, Sachs DH, Sykes M. Skin graft tolerance across a discordant xenogeneic barrier. Nat Med 1996; 2: 1211.
25. Khan A, Tomita Y, Sykes M. Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Transplantation 1995; 62: 380.
26. Acha-Orbea H, Palmer E. Mls: a retrovirus exploits the immune system. Immunol Today 1991; 12: 356.
27. Tomonari K, Fairchild S. The genetic basis of negative selection of Tcrb-V11+ T cells. Immunogenetics 1991; 33: 157.
28. Dyson PJ, Knight AM, Fairchild S, Simpson E, Tomonari K. Genes encoding ligands for deletion of Vβ11 T cells cosegregate with mammary tumour virus genomes. Nature 1991; 349: 531.
29. Bill J, Kanagawa O, Woodland D, Palmer E. The MHC molecule I-E is necessary but not sufficient for the clonal deletion of VB11 bearing T cells. J Exp Med 1989; 169: 1405.
30. Brocker T, Riedinger M, Karjalainen K. Targeted expression of major histocompatibility complex (MHC) demonstrates that dendritic cells can induce negative but not positive selection in vivo. J Exp Med 1997; 185: 541.
31. Inaba M, Inaba K, Hosono M, et al. Distinct mechanisms of neonatal tolerance induced by dendritic cells and thymic B cells. J Exp Med 1991; 173: 549.
32. Nikolic B, Sykes M. Bone marrow chimerism and transplantation tolerance. Curr Opin Immunol 1997; 9: 634.
33. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995; 332: 143.
34. Levisetti GM, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1998; 159: 5187.
35. Krieger NR, Yuh D, McIntyre B, et al. Prolongation of cardiac graft survival with anti-CD4Ig plus hCTLA4Ig in primates. J Surg Res 1998; 76: 174.
36. Lee LA, Sergio JJ, Sachs DH, Sykes M. Mechanism of tolerance in mixed xenogeneic chimeras prepared with a non-myeloablative conditioning regimen. Transplant Proc 1994; 26: 1197.
37. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349.
38. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165.
39. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med 1996; 184: 1.
40. Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181: 1869.
41. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707.
42. Tang A, Judge TA, Turka LA. Blockade of CD40-CD40 ligand pathway induces tolerance in murine contact hypersensitivity. Eur J Immunol 1997; 27: 3143.
43. Colson YL, Lange J, Fowler K, Ildstad ST. Mechanism of cotolerance in nonlethally conditioned mixed chimeras: negative selection of the Vβ T-cells receptor repertoire by both host and donor bone marrow-derived cells. Blood 1997; 88: 4601.
44. Walunas TL, Sperling AI, Khattri R, Thompson CB, Bluestone JA. CD28 expression is not essential for positive and negative selection of thymocytes or peripheral T cell tolerance. J Immunol 1996; 156: 1006.
45. Chambers CA, Cado D, Truong T, Allison JP. Thymocyte development is normal in CTLA-4 deficient mice. Proc Natl Acad Sci USA 1997; 94: 9296.
46. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270: 985.
47. Degermann S, Surh CD, Glimcher LH, Sprent J, Lo D. B7 expression on thymic medullary epithelium correlates with epithelium-mediated deletion of Vβ5+ thymocytes. J Immunol 1994; 152: 3254.
48. + thymocytes. J Immunol 1992; 149: 3217.
49. Foy TM, Page DM, Waldschmidt TJ, et al. An essential role for gp39, the ligand for CD40, in thymic selection. J Exp Med 1995; 182: 1377.
50. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256.
51. Kimikawa M, Sachs DH, C RB, Bartholomew A, Kawai T, Cosimi AB. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 709.